CD4 and chronic obstructive pulmonary disease: Additionally, the reduced Faecalibacterium longum (13.24% in COPD vs. 1.71% in HC)—a producer of anti-inflammatory butyrate, may impair mucosal immunity, potentially explaining the lower CD4+ T-cell counts in COPD patients (Kamlárová et al., 2025).